Results 131 to 140 of about 417,988 (310)

Phenytoin: A Guide to Therapeutic Drug Monitoring

Proceedings of Singapore Healthcare, 2013
Therapeutic drug monitoring of phenytoin is carried out to ensure effective and safe levels. Some of the factors complicating phenytoin dosing include a narrow therapeutic window, high degree of protein binding, and nonlinear pharmacokinetics.
Melissa Faye Wu BSc (Pharm) (Hons), Wai Hing Lim B.Pharm (Hons), M Clin Pharm   +1 more
doaj   +1 more source

Daptomycin: Physicochemical, Analytical, and Pharmacological Properties

, 2015
Daptomycin is the first approved member of a new class of antimicrobials, the cyclic lipopeptides, and presents selective action against gram-positive bacteria, including methicillin- and vancomycin-resistant strains.
Garg, Sanjay, Totoli, Eliane Gandolpho [UNESP], Nunes Salgado, Herida Regina [UNESP]   +2 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Knowledge, Attitude and Practices (K.A.P.) of doctors prescribing Vancomycin in a tertiary care hospital towards Therapeutic Drug Monitoring (T.D.M.) of Vancomycin

Recent Trends in Pharmacology
Objective: Vancomycin is frequently prescribed to treat infections caused by methicillin-resistant Staphylococcus aureus. Precise dosing through therapeutic drug monitoring is critical for optimising treatment outcomes, minimising toxicity, and reducing ...
Sujeet Bhilwade, Bhaskar Krishnamurthy, Vinayak A, Mahesh Belhekar   +3 more
doaj   +1 more source

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics.

, 2012
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increases the risk of
MacPhee IA, Abboudi H, Macphee, IA, Abboudi, H   +3 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Therapeutic drug monitoring of erlotinib in non-small cell lung carcinoma: A case study

We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma (NSCLC) and epidermal growth factor receptor (EGFR) mutation, who was treated with erlotinib, with doses adjusted by therapeutic drug monitoring (TDM).
Sureda, Manuel, Catalán Latorre, Ana, Brugarolas-Masllorens Antonio, Escudero-Ortiz, Vanesa   +3 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source